Petersen K R, Sidelmann J, Skouby S O, Jespersen J
Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark.
Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):32-8. doi: 10.1016/s0002-9378(12)90880-7.
The purpose of this study was to examine key variables in the regulation of coagulation and fibrinolysis during intake of low-dose oral contraceptives containing newly developed progestogens.
Thirty-four healthy young women were allocated to 12 consecutive cycles of treatment with monophasic combinations of 20 micrograms ethinyl estradiol and 150 micrograms desogestrel (n = 15) or 30 micrograms ethinyl estradiol and 75 micrograms gestodene (n = 19). Nonparametric analysis of variance was used for statistical evaluation.
In both groups plasma levels of fibrinogen and Factor VIIc increased, and the capacity of coagulation inhibition was affected by increased protein C and decreased protein S levels. Increased fibrinolytic capacity was indicated by elevated activity and reduced antigen levels of tissue plasminogen activator and by reduced activity and concentration of plasminogen activator inhibitor. Thrombin-antithrombin III complexes and fibrin degradation products were unchanged, signifying no effect of hormonal intake on the degree of activation of the coagulation system or the efficacy of fibrinolysis.
The overall dynamic balance between generation and resolution of fibrin was maintained during treatment with both hormonal compounds. Our findings suggest that the risk of thrombosis in normal women should not be increased.
本研究旨在检测服用含新开发孕激素的低剂量口服避孕药期间凝血和纤溶调节的关键变量。
34名健康年轻女性被分配接受连续12个周期的治疗,分别服用含20微克炔雌醇和150微克去氧孕烯的单相复方制剂(n = 15)或含30微克炔雌醇和75微克孕二烯酮的单相复方制剂(n = 19)。采用非参数方差分析进行统计学评估。
两组中纤维蛋白原和凝血因子VIIc的血浆水平均升高,凝血抑制能力受到蛋白C增加和蛋白S水平降低的影响。组织纤溶酶原激活物活性升高、抗原水平降低,纤溶酶原激活物抑制剂活性降低、浓度降低,表明纤溶能力增强。凝血酶 - 抗凝血酶III复合物和纤维蛋白降解产物未发生变化,这表明激素摄入对凝血系统的激活程度或纤溶效果没有影响。
在使用这两种激素化合物治疗期间,纤维蛋白生成与溶解之间的整体动态平衡得以维持。我们的研究结果表明,正常女性发生血栓形成的风险不应增加。